Women for science and science for women : Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention
Karim, Quarraisha Abdool (Department of Epidemiology, Mailman School of Public Health, Columbia University)
Archary, Derseree (Department of Medical Microbiology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal)
Barré-Sinoussi, Françoise (Institut Pasteur)
Broliden, Kristina (Karolinska Institutet (Estocolm, Suècia))
Cabrera Navarro, Cecilia (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Chiodi, Francesca (Karolinska Institutet (Estocolm, Suècia))
Fidler, Sarah J. (Imperial College London)
Gengiah, Tanuja N. (Centre for the AIDS Programme of Research in South Africa (CAPRISA))
Herrera, Carolina (Imperial College London)
Kharsany, Ayesha B. M. (University of KwaZulu-Natal)
Liebenberg, Lenine J. P. (University of KwaZulu-Natal)
Mahomed, Sharana (University of KwaZulu-Natal)
Menu, Elisabeth (Institut Pasteur)
Moog, Christiane (Université de Strasbourg)
Scarlatti, Gabriella (IRCCS Ospedale San Raffaele)
Seddiki, Nabila (Université Paris-Saclay)
Sivro, Aida (Public Health Agency of Canada)
Cavarelli, Mariangela (Université Paris-Saclay)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Preventing new HIV infections remains a global challenge. Young women continue to bear a disproportionate burden of infection. Oral pre-exposure prophylaxis (PrEP), offers a novel women-initiated prevention technology and PrEP trials completed to date underscore the importance of their inclusion early in trials evaluating new HIV PrEP technologies. Data from completed topical and systemic PrEP trials highlight the role of gender specific physiological and social factors that impact PrEP uptake, adherence and efficacy. Here we review the past and current developments of HIV-1 prevention options for women with special focus on PrEP considering the diverse factors that can impact PrEP efficacy. Furthermore, we highlight the importance of inclusion of female scientists, clinicians, and community advocates in scientific efforts to further improve HIV prevention strategies.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	HIV ; Women ; Prevention ; Gender equity ; PrEP ; Mucosal transmission ; Inflammation ; Microbiome
Publicat a:	Frontiers in immunology, Vol. 13 (december 2022) , ISSN 1664-3224

DOI: 10.3389/fimmu.2022.1055042
PMID: 36561760

21 p, 9.6 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats